Skip to main content
Erschienen in: Journal of Clinical Immunology 1/2010

01.05.2010

The Role of IgA and IgA Fc Receptors as Anti-Inflammatory Agents

verfasst von: Renato C. Monteiro

Erschienen in: Journal of Clinical Immunology | Sonderheft 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Materials and methods

Serum monomeric immunoglobulin A (IgA) has powerful immunomodulatory roles in its ability to suppress immune responses. Monomeric IgA acts through FcαRI, which plays a significant role in vivo in maintaining the integrity of immune responses by an inhibitory immunoreceptor tyrosine-based activation motif-mediated process and powerful inhibitory cellular effector mechanisms elicited by the IgA system.

Results

Triggering of FcαRI-mediated inhibitory function by Fab anti-FcαRI-mediated inhibitory function is able to inhibit several inflammatory and autoimmune diseases including asthma and glomerulonephritis.

Conclusion

The use of monomeric IgA as a therapeutic tool in human inflammatory diseases may offer much potential.
Literatur
1.
Zurück zum Zitat Kerr MA. The structure and function of human IgA. Biochem J. 1990;271:285–96.PubMed Kerr MA. The structure and function of human IgA. Biochem J. 1990;271:285–96.PubMed
2.
Zurück zum Zitat Solomon A. Monoclonal immunoglobulins as biomarkers of cancer. Cancer Markers. 1980;1:57–87. Solomon A. Monoclonal immunoglobulins as biomarkers of cancer. Cancer Markers. 1980;1:57–87.
3.
Zurück zum Zitat Phalipon A, Corthesy B. Novel functions of the polymeric Ig receptor: well beyond transport of immunoglobulins. Trends Immunol. 2003;24:55–8.CrossRefPubMed Phalipon A, Corthesy B. Novel functions of the polymeric Ig receptor: well beyond transport of immunoglobulins. Trends Immunol. 2003;24:55–8.CrossRefPubMed
4.
Zurück zum Zitat Boehm MK, Woof JM, Kerr MA, Perkins SJ. The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution scattering and homology modelling. J Mol Biol. 1999;286:1421–47.CrossRefPubMed Boehm MK, Woof JM, Kerr MA, Perkins SJ. The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution scattering and homology modelling. J Mol Biol. 1999;286:1421–47.CrossRefPubMed
5.
6.
7.
Zurück zum Zitat Van Epps DE, Williams Jr RC. Suppression of leukocyte chemotaxis by human IgA myeloma components. J Exp Med. 1976;144:1227–42.CrossRefPubMed Van Epps DE, Williams Jr RC. Suppression of leukocyte chemotaxis by human IgA myeloma components. J Exp Med. 1976;144:1227–42.CrossRefPubMed
8.
Zurück zum Zitat Van Epps DE, Reed K, Williams Jr RC. Suppression of human PMN bactericidal activity by human IgA paraproteins. Cell Immunol. 1978;36:363–76.CrossRefPubMed Van Epps DE, Reed K, Williams Jr RC. Suppression of human PMN bactericidal activity by human IgA paraproteins. Cell Immunol. 1978;36:363–76.CrossRefPubMed
9.
Zurück zum Zitat Wilton JM. Suppression by IgA of IgG-mediated phagocytosis by human polymorphonuclear leucocytes. Clin Exp Immunol. 1978;34:423–8.PubMed Wilton JM. Suppression by IgA of IgG-mediated phagocytosis by human polymorphonuclear leucocytes. Clin Exp Immunol. 1978;34:423–8.PubMed
10.
Zurück zum Zitat Wolf HM, Fischer MB, Puhringer H, Samstag A, Vogel E, Eibl MM. Human serum IgA downregulates the release of inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6) in human monocytes. Blood. 1994;83:1278–88.PubMed Wolf HM, Fischer MB, Puhringer H, Samstag A, Vogel E, Eibl MM. Human serum IgA downregulates the release of inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6) in human monocytes. Blood. 1994;83:1278–88.PubMed
11.
Zurück zum Zitat Nikolova EB, Russell MW. Dual function of human IgA antibodies: inhibition of phagocytosis in circulating neutrophils and enhancement of responses in IL-8-stimulated cells. J Leukoc Biol. 1995;57:875–82.PubMed Nikolova EB, Russell MW. Dual function of human IgA antibodies: inhibition of phagocytosis in circulating neutrophils and enhancement of responses in IL-8-stimulated cells. J Leukoc Biol. 1995;57:875–82.PubMed
12.
Zurück zum Zitat Wolf HM, Hauber I, Gulle H, Samstag A, Fischer MB, Ahmad RU, et al. Anti-inflammatory properties of human serum IgA: induction of IL-1 receptor antagonist and Fc alpha R (CD89)-mediated down-regulation of tumour necrosis factor-alpha (TNF-alpha) and IL-6 in human monocytes. Clin Exp Immunol. 1996;105:537–43.CrossRefPubMed Wolf HM, Hauber I, Gulle H, Samstag A, Fischer MB, Ahmad RU, et al. Anti-inflammatory properties of human serum IgA: induction of IL-1 receptor antagonist and Fc alpha R (CD89)-mediated down-regulation of tumour necrosis factor-alpha (TNF-alpha) and IL-6 in human monocytes. Clin Exp Immunol. 1996;105:537–43.CrossRefPubMed
13.
Zurück zum Zitat Olas K, Butterweck H, Teschner W, Schwarz HP, Reipert B. Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-inflammatory activities in human monocytes and peripheral blood mononuclear cells. Clin Exp Immunol. 2005;140:478–90.CrossRefPubMed Olas K, Butterweck H, Teschner W, Schwarz HP, Reipert B. Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-inflammatory activities in human monocytes and peripheral blood mononuclear cells. Clin Exp Immunol. 2005;140:478–90.CrossRefPubMed
14.
Zurück zum Zitat Jacob CM, Pastorino AC, Fahl K, Carneiro-Sampaio M, Monteiro RC. Autoimmunity in IgA deficiency: revisiting the role of IgA as a silent housekeeper. J Clin Immunol. 2008;28 Suppl 1:56–61.CrossRef Jacob CM, Pastorino AC, Fahl K, Carneiro-Sampaio M, Monteiro RC. Autoimmunity in IgA deficiency: revisiting the role of IgA as a silent housekeeper. J Clin Immunol. 2008;28 Suppl 1:56–61.CrossRef
15.
Zurück zum Zitat Pasquier B, Launay P, Kanamaru Y, Moura IC, Pfirsch S, Ruffie C, et al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity. 2005;22:31–42.PubMed Pasquier B, Launay P, Kanamaru Y, Moura IC, Pfirsch S, Ruffie C, et al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity. 2005;22:31–42.PubMed
16.
Zurück zum Zitat Wines BD, Sardjono CT, Trist HH, Lay CS, Hogarth PM. The interaction of Fc alpha RI with IgA and its implications for ligand binding by immunoreceptors of the leukocyte receptor cluster. J Immunol. 2001;166:1781–9.PubMed Wines BD, Sardjono CT, Trist HH, Lay CS, Hogarth PM. The interaction of Fc alpha RI with IgA and its implications for ligand binding by immunoreceptors of the leukocyte receptor cluster. J Immunol. 2001;166:1781–9.PubMed
17.
Zurück zum Zitat Lawrence DA, Weigle WO, Spiegelberg HL. Immunoglobulins cytophilic for human lymphocytes, monocytes and neutrophils. J Clin Invest. 1975;55:368–72.CrossRefPubMed Lawrence DA, Weigle WO, Spiegelberg HL. Immunoglobulins cytophilic for human lymphocytes, monocytes and neutrophils. J Clin Invest. 1975;55:368–72.CrossRefPubMed
18.
Zurück zum Zitat Grossetete B, Launay P, Lehuen A, Jungers P, Bach JF, Monteiro RC. Down-regulation of Fc alpha receptors on blood cells of IgA nephropathy patients: evidence for a negative regulatory role of serum IgA. Kidney Int. 1998;53:1321–35.CrossRefPubMed Grossetete B, Launay P, Lehuen A, Jungers P, Bach JF, Monteiro RC. Down-regulation of Fc alpha receptors on blood cells of IgA nephropathy patients: evidence for a negative regulatory role of serum IgA. Kidney Int. 1998;53:1321–35.CrossRefPubMed
19.
Zurück zum Zitat Launay P, Patry C, Lehuen A, Pasquier B, Blank U, Monteiro RC. Alternative endocytic pathway for immunoglobulin A Fc receptors (CD89) depends on the lack of FcRgamma association and protects against degradation of bound ligand. J Biol Chem. 1999;274:7216–25.CrossRefPubMed Launay P, Patry C, Lehuen A, Pasquier B, Blank U, Monteiro RC. Alternative endocytic pathway for immunoglobulin A Fc receptors (CD89) depends on the lack of FcRgamma association and protects against degradation of bound ligand. J Biol Chem. 1999;274:7216–25.CrossRefPubMed
20.
Zurück zum Zitat Herr AB, Ballister ER, Bjorkman PJ. Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc. Nature. 2003;423:614–20.CrossRefPubMed Herr AB, Ballister ER, Bjorkman PJ. Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc. Nature. 2003;423:614–20.CrossRefPubMed
21.
Zurück zum Zitat Davis RS, Dennis Jr G, Odom MR, Gibson AW, Kimberly RP, Burrows PD, et al. Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family. Immunol Rev. 2002;190:123–36.CrossRefPubMed Davis RS, Dennis Jr G, Odom MR, Gibson AW, Kimberly RP, Burrows PD, et al. Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family. Immunol Rev. 2002;190:123–36.CrossRefPubMed
22.
Zurück zum Zitat Blank U, Launay P, Benhamou M, Monteiro RC. Inhibitory ITAMs as novel regulators of immunity. Immunol Rev. 2009;232:59–71.CrossRefPubMed Blank U, Launay P, Benhamou M, Monteiro RC. Inhibitory ITAMs as novel regulators of immunity. Immunol Rev. 2009;232:59–71.CrossRefPubMed
23.
Zurück zum Zitat Launay P, Lehuen A, Kawakami T, Blank U, Monteiro RC. IgA Fc receptor (CD89) activation enables coupling to syk and Btk tyrosine kinase pathways: differential signaling after IFN-gamma or phorbol ester stimulation. J Leukoc Biol. 1998;63:636–42.PubMed Launay P, Lehuen A, Kawakami T, Blank U, Monteiro RC. IgA Fc receptor (CD89) activation enables coupling to syk and Btk tyrosine kinase pathways: differential signaling after IFN-gamma or phorbol ester stimulation. J Leukoc Biol. 1998;63:636–42.PubMed
24.
Zurück zum Zitat Kanamaru Y, Pfirsch S, Aloulou M, Vrtovsnik F, Essig M, Loirat C, et al. Inhibitory ITAM signaling by Fc alpha RI-FcR gamma chain controls multiple activating responses and prevents renal inflammation. J Immunol. 2008;180:2669–78.PubMed Kanamaru Y, Pfirsch S, Aloulou M, Vrtovsnik F, Essig M, Loirat C, et al. Inhibitory ITAM signaling by Fc alpha RI-FcR gamma chain controls multiple activating responses and prevents renal inflammation. J Immunol. 2008;180:2669–78.PubMed
25.
Zurück zum Zitat Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26:513–33.CrossRefPubMed Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26:513–33.CrossRefPubMed
Metadaten
Titel
The Role of IgA and IgA Fc Receptors as Anti-Inflammatory Agents
verfasst von
Renato C. Monteiro
Publikationsdatum
01.05.2010
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe Sonderheft 1/2010
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-010-9397-2

Weitere Artikel der Sonderheft 1/2010

Journal of Clinical Immunology 1/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.